Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: Neuroprotective effects when used alone or in combination with urokinase

Experimental Neurology

Volumn 161, Issue 2, 2000, Pages 733-739

  Shuaib, Ashfaq ^a   Yang, Yi ^a   Li, Qiu ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITICOLINE; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EMBOLISM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; MALE; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE;

EID: 0034055662     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7314     Document Type: Article

References (54)

1. Aronowski J., Strong R., Grotta J. C. Citicholine for the treatment of experimental cerebral ischemia: Histological and behavioral outcome. Neurol. Res. 18:1996;570-574.
2. Bednar M. M., Gross C. E., Howard D. B., Russel S. R., Thomas G. R. Nitric oxide reverses aspirin antagonism of t-PA thrombolysis in a rabbit model of thromboembolic stroke. Exp. Neurol. 146:1997;513-517.
3. Bednar M. M., Ouilley J., Russel S. R., Fuller S. P., Booth C., Howard D. B., Gross C. E. The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke. Neurosurgery. 39:1996;352-359.
4. Belayve L., Alonso O. F., Busto R., Zhao W., Ginsberg M. D. Middle cerebral artery occlusion in the rat by intraluminal suture. Stroke. 27:1996;1616-1623.
5. Bruhwyler J., Liegeois J. F., Geczy J. Facilitatory effects of chronically administered citicholine on learning and memory processes in the dog. Prog. NeuroPharmacol. Biol. Psych. 22:1998;115-128.
6. Buchan A. M., Xue D., Slivka A. A new model of temporary focal neocortical ischemia in the rat. Stroke. 23:1992;273-279.
7. Choi D. W. Methods of antagonizing glutamate neurotoxicity. Cerebrovac. Brain Metab. Rev. 2:1990;105-147.
8. Choi D. W., Rothman S. M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13:1990;171-182.
9. Clark W. M. Randomized dose-response trial of citicholine in acute ischemic stroke. Neurology. 49:1997;671-677.
10. Del Zoppo G. J., Higashida R. T., Furlan A. J., Pessin M. S., Rowley H. A., Gent M. PROCT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute cerebral artery stroke. Stroke. 29:1998;11.
11. Del Zoppo G. J. Thrombolytic therapy in acute stroke: Recent experience. Cerebrovasc. Dis. 3:1993;256-263.
12. Dixon C. E., Ma X., Marion D. W. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J. Neurotrauma. 14:1997;161-169.
13. Dorman R., Dabrowiecki V. Z., Demedio G. E., Trovarelli G., Porcellati G., Horrock L. A. Control of lipid metabolism n ischemia. Horrock L. A., Ansell G. B. Phospholipids in the Nervous System. 1982;123-135 Raven Press, New York.
14. Dyker A. G., Lees K. R. Duration of neuroprotective treatment for ischemic stroke. Stroke. 29:1998;535-542.
15. Hacke W., Kaste M., Fieschi D., Lesaffre E., Von Kummer R., Boysen G., Blumki E., Hoxter G., Mahagne M. H. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. J. Am. Med. Assoc. 274:1995;1017-1025.
16. Fresta M., Puglisi G. Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine 5I diphosphate choline. Life Sci. 61:1999;1227-1235.
17. Fresta M., Wehrli E., Puglishi G. Enhances therapeutic effect of cytidine-5-diphosphate choline when associated with GM1 containing small liposomes as demonstrated in a rat ischemia model. Pharmacol. Res. 12:1995;769-774.
18. Furlan A. J. PROCAT II: Recombinant prourokinase in acute stroke. Stroke. 30:1999.
19. Ginsberg M., Busto R. Small-animal models of global and focal cerebral ischemia. Ginsberg M., Bogousslavsky J. Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. 1998;14-35 Blackwell, Malden.
20. Green A. R., Cross A. J. Techniques for examining neuroprotective drugs in vivo. Green A. R., Cross A. L. Neuroprotective Agents and Cerebral Ischemia. 1997;47-68 Academic Press, New York.
21. Gulyás A. I., Miles R., Hájos N., Freund T. F. Precision and variability in postsynaptic target selection of inhibitory cells in the hippocampal CA3 region. Eur. J. Neurosci. 5:1993;1729-1751.
22. Hachinski V. Thrombolysis in stroke between the promise and the peril. J. Am. Med. Assoc. 276:1996;995-996.
23. Hall E. D., Pazara K. E., Braughler J. M., Linseman K. L., Jacobsen E. J. Nonsteroidal lazaroid U78 517F in models of focal and global ischemia. Stroke. 21:1990;83-87.
24. Hossmann K.-A. Animal models of cerebral ischemia. 1. Review of literature. Cerebrovasc. Dis. 1:1991;2-15.
25. Kanthan R., Shuaib A., Griebel A., Miyashita H. Glucose induced decrease in glutamate levels in ischemic human brain by microdialysis. Neurosci. Lett. 209:1996;207-209.
26. Lee J. M., Zipfel G. J., Choi D. W. The changing landscape of ischemic brain injury mechanisms. Nature. 399:1999;A7-A14.
27. Lees K. R. Does neuroprotection improve stroke outcome. Lancet. 351:1998;1448.
28. Li P.-A., Shuaib A., Li Q., Siddiqui M. M. Posttreatment with low molecular weight heparin reduces brain edema and infarction volume in rats subjected to thrombotic middle cerebral artery occlusion. Brain Res. 801:1998;220-223.
29. Li Q., Yang Y., Shuaib A. Extended protection using combination therapy of urokinase and topiramate in embolic stroke of rat. Can. J. Neurol. Sci. 25:1998;S81.
30. Lippert K., Welsch M., Krieglstein J. Over addictive protective effect of dizocilpine and NBQX antagonist against neuronal damage. Eur. J. Pharmacol. 253:1994;207-213.
31. Lyden P. D. GABA and neuroprotection. Bradley R. J., Harris R. A., Jenner P. Neurobiology. 1997;233-258 Astra Arcus, Rochester.
32. Lyden P. D., Lonzo L. Combination therapy protects ischemic brain in rats: A glutamate antagonist plus a GABA agonist. Stroke. 25:1994;189-196.
33. Lyden P. D., Zivin J. A. Hemorrhagic transformation after cerebral ischemia: Mechanisms and incidence. Cerebrovasc. Brain Metab. Rev. 5:1993;1-16.
34. McAuley M. A. Rodent models of focal ischemia. Cerebrovasc. Brain Metab. Rev. 7:1995;153-180.
35. Muir K. W., Grosset D. G. Neuroprotection for acute stroke: Making clinical trials work. Stroke. 30:1999;180-184.
36. Stroke. 28:1997;1530-1540.
37. Stroke. 28:1997;2109-2118.
38. Onal M. Z., Tatlisumak T., Sandage B. W., Fisher M. Synergistic effects of citicholine and MK 801 in temporary experimental focal ischemia in rats. Stroke. 28:1997;1065.
39. Orozco J., Mendal R., Hahn MR G. A. C. L. Influence of a 'brain protector drug' 21-amino steroid on the effects of experimental embolic treated by thrombolysis. Neurol. Res. 17:1995;423-425.
40. Overgaard K., Sereghy T., Pedersen H., Boysen G. Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke model. Neurol. Res. 15:1993;344-349.
41. Overgaard K., Sereghy T., Pedersen H., Boysen G. Effect of delayed thrombolysis with rt-PA in a rat embolic stroke model. J. Cereb. Blood Flow Metab. 14:1994;472-477.
42. Schabitz W. R., Li F., Irie K., Sandage B. W., Locke K. W., Fisher M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke. 30:1999;427-432.
43. Schabitz W. R., Weber J., Takano K., Sandage B. W., Locke K. W., Fisher M. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J. Neurol. Sci. 138:1999;21-25.
44. Shuaib A., Yang Y., Li Q. Neuroprotection and thrombolysis: Alone or in combination in a focal embolic ischemia model. Can. J. Neurol. Sci. 25:1998;S13.
45. Shuaib A., Yang Y., Li Q., Siddiqui M. M. Thrombolysis with urokinase in a focal embolic rat model. Exp. Neurol. 154:1998;330-335.
46. Siesjo B. K., Zhao Q., Pahlmark K. Glutamate, calcium and free radicals as mediators of ischemic brain damage. Ann. Thorac. Surg. 59:1995;1316-1320.
47. Siesjö B. K. Pathophysiology and treatment of focal cerebral ischemia. II. Mechanisms of damage and treatment. J. Neurosurg. 77:1992;337-354.
48. Takizawa S., Hakim A. M. Animal models of cerebral ischemia. 2. Rat models. Cerebrovasc. Dis. 1:1991;16-21.
49. New Engl. J. Med. 333:1995;1581-1587.
50. Trovarelli G., Demedio G. E., Dorman R., Piccinin V. G. L., Horrock L. A., Porcellati G. Effect of CDP-choline in ischemia-induced alterations of brain lipid in the gerbils. Neurochem. Res. 6:1981;833.
51. Wardlaw J. M., Warlow C. P. Thrombolysis in acute ischemic stroke: Does it work. Stroke. 23:1992;1826-1839.
52. Yang Y., Shuaib A., Li Q. Quantification of infarct size on focal cerebral ischemia model of rats using a simple and economical method. J. Neurosci. Methods. 84:1998;9-16.
53. Yang Y., Shuaib A., Li Q., Siddiqui M. M. Neuroprotection by delayed administration of topiramate in a rat brain model of middle cerebral artery embolization. Brain Res. 804:1998;169-176.
54. Zhang R., Chopp M., Chen H., Garcia J. H. Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. J. Neurol. Sci. 125:1994;3-10.